Back to results
US 2019/0046486 A1Published application
Compositions and methods for the treatment of neuronal injury
AssigneeAxcella Health Inc.
InventorsGianluca De Rienzo, Raffi Afeyan, Sean Carroll, Matthew Russell
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions and methods for treating or preventing neuronal injury in a subject, e.g., a subject at risk of or having traumatic brain injury or stroke.
Claims27
A composition comprising:
- a) a Branched Chain Amino Acid (BCAA) entity chosen from a leucine amino acid entity (chosen from L-leucine, oxo-leucine (alpha-ketoisocaproate (KIC)), HMB (beta-hydroxy-beta-methylbutyrate), oxo-leucine, isovaleryl-CoA, and N-acetyl-leucine or salts thereof), an isoleucine amino acid entity (chosen from L-isoleucine, 2-oxo-3-methyl-valerate (alpha-keto-beta-methylvaleric acid (KMV)), threonine, 2-oxo-3-methyl-valerate, methylbutyryl-CoA, and N-acetyl-isoleucine or salts thereof), a valine amino acid entity (chosen from L-valine, 2-oxo-valerate (alpha-ketoisovalerate (KIV)), isobutyryl-CoA, and N-acetyl-valine or salts thereof), or a combination of two or three BCAA entities;
- b) a N-acetylcysteine (NAC) entity (chosen from N-acetylcysteine, serine, acetylserine, cystathionine, glutathione, homocysteine, methionine, L-cysteine, cystine, and cysteamine or salts thereof);
- and
- c) acetyl-1-carnitine (ALCAR) or a salt thereof, or a dipeptide or salt thereof or a tripeptide or salt thereof comprising ALCAR;
- wherein at least one amino acid entity of (a)-(c) is not provided as a peptide of more than 20 amino acid residues in length,
- wherein the total wt. % of (a)-(c) is greater than the total wt. % of other protein components or non-protein components in the composition (in dry form), and
- wherein one or two amino acid entities in (a)-(c) are in one or both of free amino acid form or salt amino acid form in the composition.
4 more elements
A composition comprising:
- a) leucine, isoleucine, and valine;
- b) N-acetylcysteine (NAC);
- and
- c) acetyl-L-carnitine.
1 more element
4-6. (canceled)
(canceled)
13-15. (canceled)
A composition comprising:
- a) a Branched Chain Amino Acid (BCAA) entity chosen from a leucine amino acid entity (chosen from L-leucine, oxo-leucine (alpha-ketoisocaproate (KIC)), HMB (beta-hydroxy-beta-methylbutyrate), oxo-leucine, isovaleryl-CoA, and N-acetyl-leucine or salts thereof), an isoleucine amino acid entity (chosen from L-isoleucine, 2-oxo-3-methyl-valerate (alpha-keto-beta-methylvaleric acid (KMV)), threonine, 2-oxo-3-methyl-valerate, methylbutyryl-CoA, and N-acetyl-isoleucine or salts thereof), a valine amino acid entity (chosen from L-valine, 2-oxo-valerate (alpha-ketoisovalerate (KIV)), isobutyryl-CoA, and N-acetyl-valine or salts thereof), or a combination of two or three BCAA entities;
- b) a N-acetylcysteine (NAC) entity (chosen from N-acetylcysteine, serine, acetylserine, cystathionine, glutathione, homocysteine, methionine, L-cysteine, cystine, and cysteamine or salts thereof);
- and
- c) acetyl-1-carnitine (ALCAR) or a salt thereof, or a dipeptide or salt thereof or a tripeptide or salt thereof comprising ALCAR;
- wherein at least one amino acid entity of (a)-(c) is not provided as a peptide of more than 20 amino acid residues in length,
- wherein the total wt. % of (a)-(c) is greater than the total wt. % of other protein components or non-protein components in the composition (in dry form),
- wherein one or two amino acid entities in (a)-(c) are in one or both of free amino acid form or salt amino acid form in the composition, and
- wherein the composition is formulated as a dietary composition.
5 more elements
A method of improving one or both of neuronal function or cognitive function, comprising administering to a subject an effective amount of a composition comprising:
- a) a Branched Chain Amino Acid (BCAA) entity chosen from a leucine amino acid entity (chosen from L-leucine, oxo-leucine (alpha-ketoisocaproate (KIC)), HMB (beta-hydroxy-beta-methylbutyrate), oxo-leucine, isovaleryl-CoA, and N-acetyl-leucine or salts thereof), an isoleucine amino acid entity (chosen from L-isoleucine, 2-oxo-3-methyl-valerate (alpha-keto-beta-methylvaleric acid (KMV)), threonine, 2-oxo-3-methyl-valerate, methylbutyryl-CoA, and N-acetyl-isoleucine or salts thereof), a valine amino acid entity (chosen from L-valine, 2-oxo-valerate (alpha-ketoisovalerate (KIV)), isobutyryl-CoA, and N-acetyl-valine or salts thereof), or a combination of two or three BCAA entities;
- b) a N-acetylcysteine (NAC) entity (chosen from N-acetylcysteine, serine, acetylserine, cystathionine, glutathione, homocysteine, methionine, L-cysteine, cystine, and cysteamine or salts thereof);
- and
- c) an acetyl-1-carnitine (ALCAR) entity (chosen from acetyl-L-carnitine, lysine, trimethyllysine, trimethyl-3-OH-lysine, carnitine, O-acyl-carnitine, acyl-CoA, citrate, succinate, C3-carnitine, C5-carnitine, C4-dicarboxylcarnitine, C6-carnitine, C8-carnitine, C12:1 acylcarnitine, C14 acylcarnitine, C14:1 acylcarnitine, C16 acylcarnitine, C18:2 acylcarnitine, C18:1 acylcarnitine, and C18 acylcarnitine);
- wherein at least one amino acid entity of (a)-(c) is not provided as a peptide of more than 20 amino acid residues in length,
- wherein the total wt. % of (a)-(c) is greater than the total wt. % of other protein components or non-protein components in the composition (in dry form), and
- wherein one, two, or three amino acid entities in (a)-(c) are in one or both of free amino acid form or salt amino acid form in the composition,
- thereby improving one or both of neuronal function or cognitive function in the subject.
5 more elements
A method for treating or preventing neuronal injury, comprising administering to a subject in need thereof an effective amount of a composition comprising:
- a) a Branched Chain Amino Acid (BCAA) entity chosen from a leucine amino acid entity (chosen from L-leucine, oxo-leucine (alpha-ketoisocaproate (KIC)), HMB (beta-hydroxy-beta-methylbutyrate), oxo-leucine, isovaleryl-CoA, and N-acetyl-leucine or salts thereof), an isoleucine amino acid entity (chosen from L-isoleucine, 2-oxo-3-methyl-valerate (alpha-keto-beta-methylvaleric acid (KMV)), threonine, 2-oxo-3-methyl-valerate, methylbutyryl-CoA, and N-acetyl-isoleucine or salts thereof), a valine amino acid entity (chosen from L-valine, 2-oxo-valerate (alpha-ketoisovalerate (KIV)), isobutyryl-CoA, and N-acetyl-valine or salts thereof), or a combination of two or three BCAA entities;
- b) a N-acetylcysteine (NAC) entity (chosen from N-acetylcysteine, serine, acetylserine, cystathionine, glutathione, homocysteine, methionine, L-cysteine, cystine, and cysteamine or salts thereof);
- and
- c) an acetyl-1-carnitine (ALCAR) entity (chosen from acetyl-L-carnitine, lysine, trimethyllysine, trimethyl-3-OH-lysine, carnitine, O-acyl-carnitine, acyl-CoA, citrate, succinate, C3-carnitine, C5-carnitine, C4-dicarboxylcarnitine, C6-carnitine, C8-carnitine, C12:1 acylcarnitine, C14 acylcarnitine, C14:1 acylcarnitine, C16 acylcarnitine, C18:2 acylcarnitine, C18:1 acylcarnitine, and C18 acylcarnitine);
- wherein at least one amino acid entity of (a)-(c) is not provided as a peptide of more than 20 amino acid residues in length,
- wherein the total wt. % of (a)-(c) is greater than the total wt. % of other protein components or non-protein components in the composition (in dry form), and
- wherein one, two, or three amino acid entities in (a)-(c) are in one or both of free amino acid form or salt amino acid form in the composition,
- thereby treating or preventing the neuronal injury.
5 more elements
(canceled)
31-36. (canceled)
Dependencies are inferred from the claim text.